论文部分内容阅读
目的:探索恩替卡韦治疗慢性乙型肝炎的临床疗效。方法:经我院确诊的156例慢性乙型肝炎患者被选为研究对象且采用随机、单盲法分作两组,对照组78例患者给予拉米夫定治疗,观察组78例患者给予恩替卡韦治疗,对比两组临床治疗效果。结果:24周时观察组患者HBVDNA转阴率78.21%、HBeAg转阴率69.23%及ALT复常率82.05%与对照组比较均有明显增加(P<0.05)。48周时观察组患者HBV-DNA转阴率97.44%、HBeAg转阴率96.15%与对照组82.05%、79.49%比较均有明显增加,但两组ALT复常率均达到100.00%,组间差异无统计学意义(P>0.05)。而96周时,对照组中3例出现ALT增高,且HBV-DNA转阴后出现反弹,而观察组无上述情况,结果说明恩替卡韦耐药程度低。结论:恩替卡韦治疗慢性乙型肝炎疗效显著,能够快速抑制乙肝病毒复制,改善患者肝功能,且耐药程度低,临床应用价值高。
Objective: To explore the clinical efficacy of entecavir in the treatment of chronic hepatitis B Methods: One hundred and sixty-five patients with chronic hepatitis B confirmed by our hospital were enrolled in the study. Randomized, single-blinded patients were divided into two groups. In the control group, 78 patients were given lamivudine. In the observation group, 78 patients were given entecavir Treatment, compared with two groups of clinical treatment. Results: At 24 weeks, the HBVDNA negative rate of 78.21%, HBeAg negative rate of 69.23% and ALT normalization rate of 82.05% in the observation group were significantly higher than those in the control group (P <0.05). At 48 weeks, the rates of HBV-DNA negative conversion in the observation group were 97.44%, the HBeAg negative conversion rate was 96.15%, compared with 82.05% and 79.49% in the control group, but the ALT normalization rate in both groups reached 100.00% No statistical significance (P> 0.05). At week 96, ALT increased in 3 of the control group and rebounded after HBV-DNA turned negative, but none of the above-mentioned cases in the observation group showed that the drug resistance of entecavir was low. Conclusion: The efficacy of entecavir in the treatment of chronic hepatitis B is significant, which can rapidly inhibit the replication of hepatitis B virus and improve the liver function of patients with low drug resistance and high clinical value.